Key facts
- This page summarizes Abhinav A. Shukla's Form 4 filing for Shattuck Labs, Inc. (STTK).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Jul 2026, 19:00.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options Exercise
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person.
Footnote F2
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F3
This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer.